Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Revenue Increased 113% During First Nine Months Of 2023

 
• By Chloe Kent
  
EMA
Aflibercept represents a significant market opportunity for Formycon

More from Biosimilars

More from Products